Faslodex®, Fulvestrant is anti cancer drug belongs to the group of medicines that block the activity of estrogen. Estrogen is a female sex hormone, that can, in some cases, be involved in development of breast cancer.
- Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with hormonal therapy, or with disease relapse/progression on or after adjuvant endocrine therapy
- Faslodex, in combination with the preparation palbociclib, is intended for women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after receiving prior hormonal treatment for this ailment. When used in combination with palbociclib (Ibrance), please read the palbociclib (Ibrance) patient package insert as well.